Abstract
The life expectancy of extensive-stage small cell lung (ES-SCLC) cancer patients has not improved in the last 2-3 decades until two recent trials (CASPIAN and IMpower133) showing the addition of anti-programmed death ligand (PD-L1) therapy to chemotherapy has survival benefit over chemotherapy alone. However, such benefit is relatively small and was not even observed in some other trials using immunotherapy, raising the question of optimal chemoimmunotherapy combination in the 1st-line setting for ES-SCLC. Here, we discussed several thought-provoking questions with the focus on IMpower133 and CASPIAN trials.
Keywords:
CD155 (PVR); CD28; CD80; CTLA-4; Extensive-stage small cell lung cancer; Immunotherapy; PD-1; PD-L1; Radiation therapy; TIGIT.
Publication types
-
Letter
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
B7-H1 Antigen / antagonists & inhibitors
-
Clinical Trials, Phase III as Topic* / statistics & numerical data
-
Double-Blind Method
-
Drug Synergism
-
Etoposide / administration & dosage
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immunotherapy*
-
Lung Neoplasms / drug therapy*
-
Multicenter Studies as Topic / statistics & numerical data*
-
Neoplasm Proteins / antagonists & inhibitors
-
Organoplatinum Compounds / administration & dosage
-
Progression-Free Survival
-
Randomized Controlled Trials as Topic / statistics & numerical data*
-
Small Cell Lung Carcinoma / drug therapy*
-
Survival Analysis
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
B7-H1 Antigen
-
CD274 protein, human
-
Immune Checkpoint Inhibitors
-
Neoplasm Proteins
-
Organoplatinum Compounds
-
durvalumab
-
Etoposide
-
tremelimumab